drugset / Trial / NCT06717412
Efficacy and Safety of Low-dose Conbercept for Retinopathy of Prematurity Therapy
RandomizedParallel-groupDouble-blindTreatment
Summary
Evaluating the Optimal Effective Dose and Safety of Conbercept in Treating Retinopathy of Prematurity (ROP)
Timeline
- Start
- 2024-11-29
- Primary completion
- 2026-12-31
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Conbercept | Protein / enzyme biologic | 0.15 mg | Intravitreal |
| Subject | Conbercept | Protein / enzyme biologic | 0.25 mg | Intravitreal |